Generic Name and Formulations:
Phenylephrine HCl 2.5%; oph soln; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for MYDFRIN:
For use as a vasoconstrictor, decongestant, and mydriatic in a variety of ophthalmic conditions and procedures. Pupillary dilation in uveitis, for many ophthalmic surgical procedures and for refraction without cycloplegia. May be used for funduscopy and other diagnostic procedures.
Vasoconstriction and pupil dilation: 1 drop on the upper limbus after topical anesthesia application. Uveitis: Posterior synechiae: 1 drop applied to upper surface of cornea, repeat as necessary, not to exceed 3 times. Surgery: Apply topically 30–60 minutes before operation. Refraction: May be used with homatropine hydrobromide, cyclopentolate hydrochloride, tropicamide hydrochloride and atropine sulfate. 1 drop of cycloplegic, followed in 5 minutes by 1 drop of phenylephrine HCl oph soln. Compress lacrimal sac for 2–3 minutes after instillation to avoid excessive systemic absorption.
Ophthalmoscopic exam: 1 drop in each eye.
Untreated narrow-angle glaucoma or when untreated anatomically narrow angles are present. Low birth weight infants. Elderly with severe arteriosclerotic cardiovascular or cerebrovascular disease. Intraocular operative procedures when the corneal epithelial barrier has been disturbed.
Not for intraocular use. Sulfite sensitivity. Monitor BP in elderly with cardiac disease. Infants with cardiac anomalies. Do not exceed recommended dose. Diseased or postsurgical eye or adnexa, suppressed lacrimation (during anesthesia): may result in excessive absorption and systemic effects. Pregnancy (Cat.C). Nursing mothers.
Do not use within 21 days of MAOIs. Pressor effects may be potentiated by tricyclic antidepressants, atropine. Systemic side effects greater with concomitant β-blockers (eg, propranolol).
Cardiovascular effects esp. in elderly (eg, increase in blood pressure, syncope, myocardial infarction, tachycardia, arrhythmia, fatal subarachnoid hemorrhage).
Endocrinology Advisor Articles
- Efficacy and Safety of Alirocumab in Diabetes Mellitus
- Safety of DPP-IV Inhibitor, Cardiovascular Events After ACS in Type 2 Diabetes
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Does Maintenance of Certification Status Affect Patient Care?
- Emotional Hyper-Reactivity and Cardiometabolic Risk in Remitted Bipolar Disorder
- Reduced Mortality for Women Undergoing Assisted Reproduction Likely Due to "Healthy Patient Effect"
- Romosozumab Followed by Denosumab Effective for BMD Increase in Postmenopausal Women